idarubicin has been researched along with Autosomal Chromosome Disorders in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Creutzig, U; Reinhardt, D; Sander, A; Von Neuhoff, C | 1 |
| Dardenne, M; de Witte, T; Fenaux, P; Hayat, M; Jaksic, B; Peetermans, M; Selleslag, D; Strijckmans, P; Suciu, S; Zittoun, R | 1 |
| Hall, JL; Hamblin, TJ; Myint, H; Ross, FM | 1 |
| Andreeff, M; Beran, M; Estey, EH; Kantarjian, HM; Keating, M; Kornblau, S; O'Brien, S; Pierce, S | 1 |
1 trial(s) available for idarubicin and Autosomal Chromosome Disorders
| Article | Year |
|---|---|
Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatmen
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Europe; Humans; Idarubicin; Length of Stay; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pilot Projects; Prognosis; Prospective Studies; Survival Analysis | 1995 |
3 other study(ies) available for idarubicin and Autosomal Chromosome Disorders
| Article | Year |
|---|---|
[Genetic prognostic factors in childhood acute myeloid leukemia].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Aberrations; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 7; Cytarabine; DNA Mutational Analysis; Etoposide; Female; fms-Like Tyrosine Kinase 3; Genes, Wilms Tumor; Genetic Markers; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Nuclear Proteins; Nucleophosmin; Prognosis; Survival Rate; Translocation, Genetic | 2012 |
Early transformation to acute myeloblastic leukaemia with the acquisition of inv(16) in Ph positive chronic granulocytic leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Disorders; Chromosome Inversion; Chromosome Mapping; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Fatal Outcome; Humans; Idarubicin; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Philadelphia Chromosome | 1997 |
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Chromosome Aberrations; Chromosome Disorders; Confidence Intervals; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Environment, Controlled; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Platelet Count; Probability; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Vidarabine | 1995 |